Introduction {#Sec1}
============

Few data are available on the pharmacokinetics (PKs) of b-lactams in critically ill cirrhotic patients.

Objectives {#Sec2}
==========

*T*he objective of this study was to evaluate whether cirrhosis was associated with alterations in b-lactam concentrations when compared to other critically ill patients, and to identify the principal risk factors for inadequate concentrations in these patients.

Methods {#Sec3}
=======

We reviewed data from critically ill cirrhotic patients and matched controls in whom routine therapeutic drug monitoring (TDM) of broad-spectrum β-lactam antibiotics (ceftazidime or cefepime, CEF; piperacillin/tazobactam; TZP; meropenem, MEM) was performed. Serum drug concentrations were measured twice during the elimination phase by high-performance liquid chromatography (HPLC-UV). Antibiotic PKs were calculated using a one-compartment model. We considered therapy was adequate when serum drug concentrations were between 4 and 8 times the minimal inhibitory concentration (MIC) of *Pseudomonas aeruginosa* during optimal periods of time for each drug (≥70% for CEF; ≥ 50% for TZP; ≥ 40% for MEM).

Results {#Sec4}
=======

We studied 42 cirrhotic patients (4 for CEF, 16 for TZP and 22 for MEM) and 42 matched controls. Drug dosing was similar in the two groups. The PK analysis showed a lower volume of distribution (Vd) of MEM (p = 0.05) and a lower antibiotic clearance (CL) of TZP (p = 0.009) in patients with cirrhosis when compared to non-cirrhotic patients. More cirrhotic patients have excessive serum b-lactam concentration (p = 0.015), in particular for TZP.

Conclusions {#Sec5}
===========

Standard regimens of β-lactam resulted in excessive serum concentration in two-third of the patients in the cirrhotic cohort. These findings are mainly marked in cirrhotic patients treated by TZP, probably because of reduced drug CL.
